Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Bacterial Vaginosis Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Bacterial Vaginosis Overview | 8 | 1 |
| Pipeline Products for Bacterial Vaginosis Comparative Analysis | 9 | 1 |
| Bacterial Vaginosis Therapeutics under Development by Companies | 10 | 1 |
| Bacterial Vaginosis Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Bacterial Vaginosis Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Bacterial Vaginosis Products under Development by Companies | 15 | 1 |
| Bacterial Vaginosis Products under Investigation by Universities/Institutes | 16 | 1 |
| Bacterial Vaginosis Companies Involved in Therapeutics Development | 17 | 6 |
| Alfa Wassermann S.p.A | 17 | 1 |
| AmVac AG (Inactive) | 18 | 1 |
| Evofem, Inc. | 19 | 1 |
| Osel, Inc. | 20 | 1 |
| Starpharma Holdings Limited | 21 | 1 |
| Symbiomix Therapeutics, LLC | 22 | 1 |
| Bacterial Vaginosis Therapeutics Assessment | 23 | 7 |
| Assessment by Monotherapy Products | 23 | 1 |
| Assessment by Target | 24 | 1 |
| Assessment by Mechanism of Action | 25 | 1 |
| Assessment by Route of Administration | 26 | 2 |
| Assessment by Molecule Type | 28 | 2 |
| Drug Profiles | 30 | 18 |
| Amphora Drug Profile | 30 | 2 |
| AMV-100 Drug Profile | 32 | 1 |
| astodrimer Drug Profile | 33 | 4 |
| benzoyl peroxide Drug Profile | 37 | 1 |
| LACTIN-V Drug Profile | 38 | 1 |
| rifaximin Drug Profile | 39 | 4 |
| secnidazole Drug Profile | 43 | 2 |
| Small Molecule for Bacterial Vaginosis and Candidiasis Drug Profile | 45 | 1 |
| subtilosin Drug Profile | 46 | 1 |
| TOL-463 Drug Profile | 47 | 1 |
| Bacterial Vaginosis Dormant Projects | 48 | 1 |
| Bacterial Vaginosis Discontinued Products | 49 | 1 |
| Bacterial Vaginosis Product Development Milestones | 50 | 10 |
| Featured News &Press Releases | 50 | 1 |
| May 26, 2016: Symbiomix Therapeutics Announces Positive Results from Phase 3 Trial of SYM-1219 for Bacterial Vaginosis, and Pre-NDA Meeting with FDA Supportive of 2016 NDA Filing | 50 | 1 |
| May 11, 2016: Osel Lead Product LACTIN-V Enters Phase 2b Study to Prevent Recurrence of Bacterial Vaginosis | 50 | 1 |
| Mar 31, 2016: Evofem Files IND for Evaluation of Prevention of Recurrence of Bacterial Vaginosis | 51 | 1 |
| Jan 11, 2016: Evofem Holdings Announces Successful Completion of Pre-IND Meeting for Amphora | 52 | 1 |
| Oct 14, 2015: Additional US Patent granted for VivaGel BV | 52 | 1 |
| Sep 24, 2015: EU Marketing Approval Granted for VivaGel BV | 53 | 1 |
| Sep 21, 2015: Symbiomix Therapeutics Presents Data at ICAAC/ICC Demonstrating Oral Pharmacokinetics of Lead Product SYM-1219 Administered With and Without Food | 53 | 1 |
| Aug 27, 2015: Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation | 54 | 1 |
| Aug 06, 2015: Symbiomix Therapeutics' First Pivotal Trial Results for SYM-1219 for Bacterial Vaginosis Presented at IDSOG | 55 | 1 |
| Jun 09, 2015: Symbiomix Therapeutics Doses First Patient in Confirmatory Phase 3 Pivotal Study of Lead Drug Candidate SYM-1219 for Bacterial Vaginosis | 56 | 1 |
| May 05, 2015: Symbiomix Therapeutics Announces Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis | 56 | 1 |
| Mar 04, 2015: Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated | 57 | 1 |
| Nov 21, 2014: SYM-1219 Chosen as one of the Top Infectious Disease Projects to Watch by Therapeutic Area Partnerships | 58 | 1 |
| Sep 09, 2014: Symbiomix Therapeutics Makes First Corporate Announcement: Completion of Enrollment in a Phase 2 Clinical Trial of SYM-1219 for Bacterial Vaginosis | 58 | 1 |
| Jul 14, 2014: FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial | 59 | 1 |
| Appendix | 60 | 2 |
| Methodology | 60 | 1 |
| Coverage | 60 | 1 |
| Secondary Research | 60 | 1 |
| Primary Research | 60 | 1 |
| Expert Panel Validation | 60 | 1 |
| Contact Us | 60 | 1 |
| Disclaimer | 61 | 1 |